The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).

Kevin  Kalinsky

Employment - EQRx (I); GRAIL (I)

Stock and Other Ownership Interests  - EQRx (I); GRAIL (I)

Consulting or Advisory Role - 4D Pharma; AstraZeneca; Cullinan Oncology; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; eFFECTOR Therapeutics; Genentech/Roche; immunomedics; Lilly; Menarini Silicon Biosystems; Merck; mersana; Myovant Sciences; Novartis; Oncosec; Prelude Therapeutics; Puma Biotechnology; RayzeBio; RayzeBio; Seagen; Takeda

Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)

Other Relationship - Genentech; Immunomedics

William E.  Barlow

Research Funding - AstraZeneca (Inst); Merck (Inst)

Harsh B  Pathak

No Relationships to Disclose

Julie R.  Gralow

No Relationships to Disclose

Kathy S.  Albain

Honoraria - Encore Medical Education

Research Funding - Quantum Leap Healthcare Collaborative (Inst); Seagen (Inst)

Other Relationship - Seagen

Daniel F.  Hayes

Stock and Other Ownership Interests  - Cellworks; InBiomotion; Xilis

Honoraria - Tempus

Consulting or Advisory Role - Artera; Arvinis; bioTheranostics; BioVica; Cellworks; Centrix; Cepheid; Epic Sciences; Exact Sciences; Freenome; Guardant Health; L-Nutra; Macrogenics; Oncocyte; Strata Oncology; Stratipath; Tempus; Turnstone Bio; xilis

Research Funding - Angle (Inst); AstraZeneca (Inst); Cepheid/Danaher (Inst); Menarini Silicon Biosystems (Inst); Pfizer (Inst)

Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.

Other Relationship - Cancer Expert Now; UpToDate

Nancy U.  Lin

Stock and Other Ownership Interests  - Artera

Consulting or Advisory Role - Artera; AstraZeneca; Blueprint Medicines; Daiichi Sankyo; Eisai; Johnson & Johnson/Janssen; Menarini; Olema Pharmaceuticals; Pfizer; Seagen

Research Funding - Genentech (Inst); Merck (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Zion Pharma (Inst)

Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases; Royalties, Jones & Bartlett

Travel, Accommodations, Expenses - Olema Pharmaceuticals

Edith A.  Perez

Employment - Bolt Biotherapeutics

Leadership - Bolt Biotherapeutics

Stock and Other Ownership Interests  - Genentech/Roche

Consulting or Advisory Role - Daiichi Sankyo; Puma Biotechnology; Seagen

Lori J.  Goldstein

Honoraria - AstraZeneca; Biovica; Daiichi Sankyo; Immunomedics

Consulting or Advisory Role - AstraZeneca; Biovica; Immunomedics

Research Funding - Genentech/Roche (Inst); Merck (Inst)

Other Relationship - Daiichi Sankyo

Stephen K. L.  Chia

Honoraria - AstraZeneca; Gilead Sciences; Lilly; Merck; Novartis; Pfizer

Research Funding - AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst)

Priya  Rastogi

Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Lilly

Anne F.  Schott

Research Funding - Arvinas (Inst); Celcuity (Inst); Genentech/Roche (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Takeda (Inst)

Patents, Royalties, Other Intellectual Property - Contributor of 2 "cards" on breast cancer topics to UpToDate; Systems and Methods for Tissue Imaging, 8,185,186, Inventor, Submitted on 04/2008. This is a patent for use of diffusion MRI technology to quantitate response to neoadjuvant breast cancer therapy.

Steven  Shak

Employment - Exact Sciences; Roche (I)

Leadership - Exact Sciences

Stock and Other Ownership Interests  - Exact Sciences

Consulting or Advisory Role - Exact Sciences; Genomic Life

Patents, Royalties, Other Intellectual Property - Filed Oncotype DX patents (Inst)

Debashish  Tripathy

Consulting or Advisory Role - Ambrx; AstraZeneca; Genomic Health; Gilead Sciences; GlaxoSmithKline; Menarini; Novartis; OncoPep; Personalis; Pfizer; Roche; Sermonix Pharmaceuticals

Research Funding - Ambrx (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Novartis

Gabriel N.  Hortobagyi

Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Novartis; Seagan

Funda  Meric-Bernstam

Employment - MD Anderson Cancer Center

Honoraria - Dava Oncology

Consulting or Advisory Role - Abbvie; AstraZeneca; Black Diamond Therapeutics; Calibr; Daiichi Sankyo/Astra Zeneca; EcoR1 Capital; Eisai; Exelixis; GT Aperion; Incyte; Infinity Pharmaceuticals; Karyopharm Therapeutics; LegoChem Biosciences; Lengo Therapeutics; Menarini Group; OnCusp Therapeutics; Protai; Seagen; Tallac Therapeutics; Theratechnologies; Zentalis; Zymeworks

Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)

Travel, Accommodations, Expenses - ARTIDIS; Cholangiocarcinoma Foundation; Dava Oncology; ESMO; European Organisation for Research and Treatment of Cancer (EORTC)

Priyanka  Sharma

Stock and Other Ownership Interests  - Amgen; Gilead Sciences (I); Johnson & Johnson/Janssen; Pfizer (I); Roche/Genentech (I); Sanofi

Consulting or Advisory Role - AstraZeneca; Boston Scientific (I); Cipla (I); Gilead Sciences; GlaxoSmithKline; Merck; Novartis; Pfizer; Salient Pharmaceuticals (I); Sanofi

Research Funding - Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst)

Patents, Royalties, Other Intellectual Property - UpToDate

Lajos  Pusztai

Honoraria - Athenex; bioTheranostics; natera; OncoCyte

Consulting or Advisory Role - Almac Diagnostics; AstraZeneca; Bristol Myers Squibb; Clovis Oncology; Eisai; H3 Biomedicine; Immunomedics; Merck; Novartis; Pfizer; Roche/Genentech; Seagen; Syndax

Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)

Travel, Accommodations, Expenses - AstraZeneca

(OPTIONAL) Uncompensated Relationships - Foundation Medicine; NanoString Technologies

Alastair Mark  Thompson

Employment - Lilly (I)

Stock and Other Ownership Interests  - Lilly (I)

Travel, Accommodations, Expenses - Endomagnetics

Andrew K.  Godwin

Employment - University of Kansas Health System

Stock and Other Ownership Interests  - Clara Biotech; Exokeryx

Honoraria - Sinochips Kansas

Consulting or Advisory Role - Biovica

Research Funding - BioFluidica (Inst); Clara Biotech (Inst); Predicine (Inst); VITRAC Therapeutics (Inst)

Patents, Royalties, Other Intellectual Property - Provisional - US Patent number 63/391,657 entitled “Extracellular Vesicle Proteomic Biomarker Panel for Ovarian Cancer Screening and the Early Detection of Disease”. (Inst); Provisional - US Patent number 63/496,270 entitled “Treatment of Neoplasm by Inhibiting KIF15”. (Inst); Provisional Patent application entitled - "WJMSC-Derived Small Extracellular Vesicle (sEVs) Enhance T Cell Suppression Through Checkpoint PD-L1" - Dr. Joseph McGuirk (applicant) (Inst)